Companies

a Hong Kong-listed recombinant-collagen producer behind the consumer brand Kefumei (可复美), which had its second recombinant-collagen implant medical device approved in China in 2026, extending beyond topical cosmetics into medical aesthetics.

markets SIR-Spheres Yttrium-90 microspheres (Yigantai) for selective internal radiation therapy of liver cancer, and its US DOORwaY90 clinical trial met its primary endpoint for unresectable hepatocellular carcinoma; the company is building China's largest radiopharmaceutical production base in Wuhan.

completed the first newbuilding application of its next-generation Hempaguard NB silicone hull coating in 2026, integrating it directly into the shipbuilding process with Maersk and Yangzijiang Shipyard rather than applying it only as a retrofit.

supplies pharmaceutical-grade chitosan and custom chitosan oligomers under GMP conditions to European drug developers and researchers.

Photothermal superhydrophobic protective coatings — Combined anti-icing/anti-corrosion marine coating research.

the world's leading supplier of non-carrier-added Lutetium-177, with a Lu-177 manufacturing collaboration with the Institut Laue-Langevin dating to 2009 and a fresh 2026 supply agreement with Radiopharm Theranostics.

an early-stage startup pursuing XY-to-XX cell reprogramming so that same-sex couples can have children who share both partners' genetic material, without requiring donor eggs or sperm.

markets Epidiolex, the FDA-approved plant-derived CBD drug for severe childhood epilepsy, reporting 15% year-on-year sales growth in Q1 2026 as part of 19% overall company revenue growth.

markets the Seaquantum Ultra S self-polishing silyl-acrylate antifouling coating and unveiled its expanded Hull Performance Solutions (HPS 2.0) coating system in 2026.

its Superfloc RH4821 anionic rheology modifier outperformed a previous flocculant in a full-scale tailings-thickening trial at a Brazilian mining site, and its Superfloc BioMB line applies a biomass-balanced approach to polyacrylamide flocculants for sustainable wastewater treatment.

markets Functional Keratin® ingredients across personal care, nutraceuticals and wound care, including keraGEN-IV®, an ingestible keratin-derived peptide product for hair, skin and nail health, alongside its keratin-based wound-care lines.

supplies bulk hot-liquid keratin gel products (its keraGEL® line) derived from wool-processing byproducts, alongside its established lanolin/wool-grease business.

produces fermentation-derived fungal chitosan, certified and marketed as a vegan alternative to synthetic and crustacean-sourced polymers for health, beauty and agricultural applications.

the academic origin of the XY-to-XX chromosomal reprogramming technique and of ongoing work reconstituting germ-cell and gonadal development for in-vitro gamete production, published across Nature-family and Science journals and pursued in collaboration with European labs.

conducts long-term preclinical xenotransplantation research, including deep phenotyping of early human anti-porcine xenograft immune responses and studies defining which genetic modifications of source pigs are essential for successful cell, tissue and organ xenotransplantation.

a leading European academic hub studying molecular aging pathways (IIS, mTOR) in model organisms and coordinating geroprotector research across the EU.

pursuing bottom-up synthetic biology, including minimal approaches to synthetic cell construction and the design of photosynthetic synthetic organisms.

ran a Phase 1 trial of the senolytic combination dasatinib plus quercetin (D+Q) in diabetic kidney disease, directly measuring reduced senescent-cell burden in treated patients.

its miroliverELAP, a bioengineered extracorporeal liver support device built from decellularized porcine liver matrix recellularized with human cells, received FDA RMAT (Regenerative Medicine Advanced Therapy) designation.

developed a DNA nanorobot loaded with the clotting protein thrombin and an AS1411 nucleolin-targeting aptamer, designed to open specifically at tumor vasculature and trigger local, targeted clotting — a landmark in-vivo demonstration of the aptamer-lock mechanism.

derives its ChitoClear chitosan line from deep-water shrimp (Pandalus borealis) shells sourced in the North Atlantic, and has extended into cosmetic-grade ChitoCare ingredients for skincare formulations.

a DEA-licensed (Schedule I-V) bulk manufacturer of ultra-high-purity CBD/THC isolates under FDA Drug Master File and GMP certification, recently acquired by Siegfried, a global pharmaceutical CDMO.

develops SSTR2-targeted radiopharmaceutical therapies for gastroenteropancreatic neuroendocrine tumors and operates a dedicated Indianapolis hub for end-to-end manufacturing and on-demand delivery of its clinical-stage RPT candidates.

its 10-gene-edited UHeart received FDA clearance to proceed with the EXPRESS clinical trial, an adaptive Phase 1/2/3 design for pig-heart xenotransplantation, following the first-ever living-patient pig-heart transplants performed under FDA expanded access.

develops selective senolytics using its AI-driven ALEMBIC platform; its lead candidate RLS-1496, a topical GPX4 modulator, reported positive preliminary Phase 1 results in plaque psoriasis, atopic dermatitis and skin aging.

a leading European gene-therapy research institute exploring epigenetic editing to improve CAR-T cell function (reducing T-cell exhaustion), and in 2026 announced a manufacturing-scale-up collaboration with Cytiva to address gene-therapy production bottlenecks.

uses zinc-finger transcription factors rather than dCas9 as its DNA-binding scaffold, partnering with Genentech to develop an epigenetic Alzheimer's therapy and holding patent filings on zinc-finger repressors targeting alpha-synuclein.

develops DNA-origami-based programmable containers and nanomachines — including lipid-inspired origami containers for biomolecular robotics — extending structural DNA nanotechnology toward autonomous, moving nanodevices.

its Tidal Clear platform, including the ACHPlus hybrid coagulant (alkaline ferric chloride plus precision chitosan formulations), reduces chemical use and sludge volume in water treatment as a closed-loop, non-toxic alternative to synthetic polyacrylamide.

conducts epigenetic-editing and inheritance research relevant to congenital conditions such as muscular dystrophy, alongside China's broader academic epigenetics research base.

its TEMPO platform produced TUNE-401, an IV-delivered LNP-RNA epigenetic silencer that reported positive Phase 1b/2a proof-of-concept data at EASL 2026 as a first-in-class epigenetic therapy for hepatitis B.

its lead senolytic, UBX1325 (a Bcl-xL inhibitor), has produced 36-week clinical results and a NEJM Evidence publication supporting long-term vision improvement in diabetic macular edema and retinal disease.

Biosynthetic CBGA/CBG, API licensing with Laurus Labs — Engineered prenyltransferase (NphB quadruple mutant).

a dermocosmetics brand focused on sensitive-skin barrier repair, positioning itself with a dermatological/clinical-science identity in the competitive domestic skincare market.

is running an FDA-regulated clinical trial of porcine skin xenotransplantation for complete wound closure in mixed-depth burns.

sells ultra-thin, flexible printed e-paper displays embedded directly in packaging, including Smart E-Paper Expiry Date Labels that replace static printed dates with an electronically updated readout.

Providing ultra-high-throughput mapping of protein-protein interactions, essential for generating the massive datasets required to train the next generation of predictive models.

Delivery platforms — Vector engineering.

CDMO services — Scalable GMP manufacturing.

Plasmid Repository — Automated distribution.

Manufacturer of Pro-Kolin — a synbiotic paste with pectin and kaolin that is the European standard for acute GI distress in companion animals. Combines probiotics with prebiotic fibres in a high-adhesion paste format.

precision biologicals including the Howler biofungicide and plant-health compositions, built on a proprietary microbial-genomics platform.

Mónafil® — Peat-based biofiltration.

Process engineering — Turnkey facility design.

ear-tag and collar monitoring across dairy, beef and cow-calf herds, integrated with a veterinary health platform.

Industrial tech — Scaling and MRV protocols.

Offset registry — Methodologies for voluntary and compliance markets.

Expanded Cork Board — Steam expansion.

MónaShell® — Shell-based biofiltration.

Biocommodities pricing indices — Global standard CIF ARA and FOB Baltic quotes.

Protein Design — Computational design.

Clinical pipelines — Accelerated trials.

ampliTex flax prepregs — High-performance natural fiber grids.

Mega-scale MSW plants — 20k tons/day AD capacity.

Phycocyanin — Food-grade pigments.

Biofib' Trio — Multi-fiber blends.

Developing cross-modal, hundred-billion-parameter protein LLMs designed to computationally generate and optimize complex multi-specific antibodies and enzymes.

Delivery platforms — Vector engineering.

Advanced therapeutics — Precision targeting.